Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech develops and manufactures biosimilar medicines for global markets. Company news centers on its approved and marketed biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, along with disclosed candidates for autoimmune disorders, eye disorders, osteoporosis, respiratory disease and cancer.
Recurring updates cover financial results, annual reporting, FDA interactions tied to the Reykjavik manufacturing facility, biosimilar study results such as AVT80, supply and commercialization partnerships, intellectual-property settlements, executive changes and manufacturing-platform developments. Alvotech also reports on global commercial reach through partners across the United States, Europe, Japan, China and other international markets.
Alvotech (NASDAQ: ALVO) reached a global licensing and settlement agreement with Regeneron and Bayer resolving all remaining patent disputes for its aflibercept (Eylea) biosimilar. The deal grants worldwide manufacturing and supply rights to Alvotech’s partners and enables staged market entry beginning January 1, 2026.
Market dates include UK and Canada from Jan 1, 2026, Japan limited indications from May 1, 2026, broader Japan indications from Nov 1, 2026, and other countries (excluding U.S.) from May 1, 2026. Remaining terms are confidential.
Alvotech (NYSE:ALVO) disclosed corrected filings to the Luxembourg CSSF reporting manager and closely associated person transactions by ATP Holdings ehf. The filings show an acquisition of 4,812,257 shares on December 17, 2025 and a sale of 2,110,640 shares on December 19, 2025, both at SEK 44.06 per share. The notice corrects an earlier version that mischaracterized the December 19, 2025 transaction. Attachments reference two CSSF filings dated January 5, 2026.
Alvotech (ALVO) disclosed two manager/closely associated person transactions recorded in filings with the Luxembourg CSSF. ATP Holdings ehf acquired 4,812,257 shares on December 17, 2025 and 2,110,640 shares on December 19, 2025 at a transaction price of SEK 44.06 per share, for a combined total of 6,922,897 shares. The disclosures are attached and list investor relations contact Benedikt Stefansson.
Alvotech (NASDAQ: ALVO) announced a planned CEO succession: founder Róbert Wessman will step down as CEO at the end of Q1 2026 and continue as Executive Chairman in a full-time capacity and as the company’s largest shareholder. Lisa Graver is appointed Chief Executive Officer and will relocate her professional base to Iceland; she will step down from the Alvotech Board when she assumes the CEO role.
The company said the transition begins immediately, highlights a pipeline of 30 products in development, and notes five products on the market sold globally.
Alvotech (NASDAQ: ALVO) secured a USD 100 million senior term loan facility maturing in December 2027 to bolster liquidity and support R&D and global product launches through 2026. The loan carries a 12.50% annual interest rate, payable monthly in cash, and replaces the company's prior working capital ABL, giving access to the full USD 100 million during the two-year term.
The financing was led by GoldenTree Asset Management and follows prior refinancing and repricing actions, including a repriced facility at SOFR+6.0% (~9.8%) and a USD 108 million convertible bond placing due 2030.
Alvotech (ALVO) filed a notification with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) on 29 Dec 2025 regarding changes in the company's own shares. An attachment titled Alvotech Own Shares Notification 29 Dec 2025 was submitted with the filing. Investors should review the attached notification for the specific details and scope of the share changes.
Alvotech (NASDAQ: ALVO) published its 2026 financial calendar with scheduled dates for interim and annual results, investor calls and the annual general meeting. Results are released after U.S. market close and an investor call follows the next day.
- Mar 18, 2026 – Q4 2025 / full-year 2025 results
- May 6, 2026 – Q1 2026 results
- Jun 3, 2026 – Annual General Meeting (Luxembourg)
- Aug 19, 2026 – Q2 2026 / first six months
- Nov 11, 2026 – Q3 2026 / first nine months
- Mar 10, 2027 – Q4 2026 / full-year 2026
All dates are subject to change. Investor relations contacts were provided for follow-up.
Alvotech (NASDAQ: ALVO) announced European launches beginning December 22, 2025 for Gobivaz (golimumab, AVT05), its biosimilar to Simponi. Gobivaz is described as the first marketed biosimilar to Simponi worldwide and will be commercialized exclusively in Europe by partner Advanz Pharma. In the UK, adoption is supported by an NHS England tender award, providing a defined procurement framework. Availability across EEA countries will follow national pricing and reimbursement processes. Approval was supported by analytical, pre-clinical and clinical studies; Gobivaz is offered in the same presentations and dosages as the reference product and is manufactured at Alvotech’s facility in Iceland.
Alvotech (NASDAQ: ALVO) and Teva reached a settlement and license agreement with Regeneron allowing Alvotech’s proposed biosimilar AVT06 (aflibercept) to be marketed in the U.S. in Q4 2026, or earlier under certain circumstances, if approved by the FDA. AVT06 has received marketing approvals in the United Kingdom, Japan and the 30 countries of the European Economic Area. A January 2024 confirmatory clinical study met its primary endpoint, showing high similarity to Eylea® in neovascular AMD. The settlement and Teva partnership position Alvotech for a potential U.S. launch pending FDA approval.
Alvotech (NASDAQ: ALVO) has placed USD 108 million senior unsecured convertible bonds due 22 December 2030 in a significantly oversubscribed private offering.
The bonds carry a 6.875% coupon, are issued at par, convert from day 41, and have an initial conversion price of USD 5.9224 (25% premium over USD 4.7379). Net proceeds will fund R&D, scaling production and four global product launches through 2026; the company expects R&D spend of about USD 250 million in 2026.
Concurrent activity included a USD ~56 million placement of existing shares to hedge bond investors, a full stock-lending facility, and lock-ups of 3 and 12 months for new shares and equity-linked securities.